Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T19:41:20.933Z.
Calculation as of: 2026-10-06T19:41:20.933Z.
Quote observation: 2026-10-06T19:40:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e7bb4fe4bb3aa983eb4620adc8aa5d0f555a5020ff21ce65ee2b72f9631e0f85
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$3.00B
PS Ratio
6.46
TTM Avg
9.18
3Y Avg
9.54
5Y Avg
123.98
Market Cap
$2.67B
PS Ratio
0.79
TTM Avg
0.64
3Y Avg
1.30
5Y Avg
1.84
Market Cap
$3.06B
PS Ratio
847.71
TTM Avg
1171.95
3Y Avg
915.38
5Y Avg
373.66
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | $2.86B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.77B | 4.15 | 7.07 | 9.70 | 14.76 |
| AtriCure, Inc. (ATRC)vs › | $2.73B | 4.79 | 3.27 | 3.39 | 5.20 |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.00B | 6.46 | 9.18 | 9.54 | 123.98 |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.01B | N/A | N/A | N/A | N/A |
| Precigen, Inc. (PGEN)vs › | $2.70B | 31.51 | 132.61 | 101.64 | 68.12 |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.67B | 0.79 | 0.64 | 1.30 | 1.84 |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | 847.71 | 1171.95 | 915.38 | 373.66 |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.66B | N/A | N/A | N/A | N/A |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.65B | 1.02 | 0.82 | 0.54 | 0.45 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-02 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-11 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-29 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
